Immunai
New York
About Immunai
Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $295.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2021)
- Website: immunai.com
- Phone: 1 646 588 1041
Industries & Categories
Analytics, Artificial Intelligence (AI), Biotechnology, Machine Learning, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunai-27165 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.